Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 656 clinical trials
18F-PSMA-1007 PET Imaging to Detect Primary Prostate Cancer

To study the added value of 18F-PSMA-1007 PET to mpMRI in the detection of local prostate cancer lesions.

digital rectal examination
multiparametric magnetic resonance imaging
pet/ct scan
positron emission tomography
  • 0 views
  • 19 Feb, 2024
PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy)

Open-label, multicenter, dose titration and expansion three-arm trial to evaluate the safety, tolerability, immunogenicity, and preliminary efficacy of W_pro1 cancer vaccine (W_pro1) in patients with metastatic castration resistant prostate cancer (mCRPC) W_pro1 in combination with goserelin acetate with or without cemiplimab, in patients with high-risk, localized prostate cancer (LPC)

abiraterone
adenocarcinoma of prostate
goserelin
carcinoma
gonadorelin
  • 2 views
  • 19 Feb, 2024
Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer

This is a single-arm Phase II clinical trial assessing the clinical efficacy of prostate specific membrane antigen (PSMA) PET/MR guided MR-LINAC based SBRT-SIB with planned accrual of 50 patients.

metastasis
hbed-cc
adenocarcinoma of prostate
stereotactic body radiation therapy
adenocarcinoma
  • 16 views
  • 19 Feb, 2024
Oral EPI-7386 in Patients With Metastatic Castration-Resistant Prostate Cancer

This is a phase I, clinical research study of EPI-7386, an investigational drug being studied as a treatment for patients with prostate cancer. All patients in the study will receive EPI-7386. Since this is the first study of EPI-7386 in humans, there is no information about how it affects people …

diphosphonates
soft tissue disease
castration-resistant prostate cancer
metastasis
progressive disease
  • 0 views
  • 19 Feb, 2024
Lutetium-177-PSMA-I&T in Oligo-metastatic Hormone Sensitive Prostate Cancer

  Radioligand therapy (RLT) using Lutetium-177 labelled PSMA is a promising new therapeutic approach to treat metastatic prostate cancer. This tumor-specific treatment is directed against prostate-specific membrane antigen (PSMA), which is overexpressed in prostate cancer cells.

metastatic prostate cancer
taxane
pet/ct scan
abiraterone
adenocarcinoma of prostate
  • 4 views
  • 19 Feb, 2024
18F-DCFPyL PET/CT Impact on Treatment Strategies for Patients With Prostate Cancer

The main purpose of this phase II trial study is to determine whether a positron emission tomography (PET)/computed tomography (CT) scan using 18F-DCFPyL affects the clinical management plan in Veterans. In this study, the management plan prior to and after 18F-DCFPyL PET/CT will be recorded by specific questionnaires and corresponding …

metastatic prostate cancer
external beam radiation therapy
pet/ct scan
adenocarcinoma of prostate
conventional imaging
  • 0 views
  • 19 Feb, 2024
Study to Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of CC-94676 in Subjects With Metastatic Castration-Resistant Prostate Cancer

This is a first in human study to assess the safety, tolerability, PK, PD and preliminary efficacy of CC-94676 in men with progressive metastatic castration-resistant prostate cancer.

androgen suppression
castration-resistant prostate cancer
abiraterone
adenocarcinoma of prostate
prostate cancer
  • 0 views
  • 19 Feb, 2024
ATR Inhibitor BAY 1895344 Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer

The purpose of the study is to test how well patients with advanced solid tumors and ovarian cancer respond to treatment with BAY1895344 in combination with niraparib. In addition researchers want to find for patients the optimal dose of BAY1895344 in combination with niraparib, how the drug is tolerated and …

serum pregnancy test
niraparib
solid tumour
prostate cancer
cancer
  • 0 views
  • 19 Feb, 2024
Expanded Access of Omidubicel for Allogeneic Transplantation in Patients With Hematological Malignancies

Omidubicel is an investigational therapy for patients with high-risk hematologic malignancies.

allogeneic transplantation
investigational treatment
cancer
hematologic malignancy
  • 0 views
  • 19 Feb, 2024
Real-Time Monitoring of Chemotherapy Side-Effects in Patients With Gastrointestinal Cancers RT-CAMSS Study

This trial tests new methods and materials for the real-time chemotherapy-associated side effects monitoring support system (RT-CAMSS) in patients with gastrointestinal cancers undergoing chemotherapy. RT-CAMSS is a monitoring support system that provides patients with evidence-based information and side-effect management and coping skills, emotional support and validation, and proactive care via …

taxol
stage iii colorectal cancer ajcc v8
pancreatic cancer
carboplatin
folfox regimen
  • 0 views
  • 19 Feb, 2024